RxDoctor Payments Data

Satyavath Sharma, MD

Internal Medicine · Mount Vernon, NYNPI 1932202074

Payments from drug & device makers

$2,680in general payments, 2019–2025

Across 123 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$369
  • Exact Sciences$324
  • AstraZeneca$281
  • Novartis$203
  • Neurocrine Biosciences, Inc.$178
  • AbbVie$173
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,680100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,680 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$191,896
Medicare patients
145
Services billed
2,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide14$111,364
JanuviaSitagliptin Phosphate81$98,466
EliquisApixaban181$86,545
RybelsusSemaglutide36$86,325
JanumetSitagliptin Phos/Metformin Hcl28$37,069
FarxigaDapagliflozin Propanediol26$29,090
JardianceEmpagliflozin55$27,054
Repatha SureclickEvolocumab31$25,798
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,246
OzempicSemaglutide16$15,162
MounjaroTirzepatide11$13,700
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog45$12,712
EntrestoSacubitril/Valsartan24$12,518
NuedextaDextromethorphan Hbr/Quinidine15$11,047
KerendiaFinerenone14$9,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$59$135,535109 claims
Novo NordiskRybelsus, Ozempic$125$101,48752 claims
PfizerEliquis$43$86,545181 claims
Boehringer IngelheimJardiance, Tradjenta$96$35,94369 claims
AstraZenecaFarxiga, Lokelma, Symbicort$281$35,03653 claims
GSKTrelegy Ellipta, Breo Ellipta$25$27,32648 claims
Lilly USA, LLCMounjaro$47$13,70011 claims
NovartisEntresto$203$12,51824 claims
Avanir Pharmaceuticals, Inc.Nuedexta$40$11,04715 claims
BayerKerendia$106$9,82114 claims
Astellas Pharma US IncMyrbetriq$90$8,80018 claims
AbbVieLumigan$173$5,12519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Mount Vernon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →